HLA-DQB1*0303 and *0301 alleles influence susceptibility to and prognosis in cutaneous malignant melanoma in the British Caucasian population

Tissue Antigens

Volumn 52, Issue 1, 1998, Pages 67-73

  Bateman, A C ^a   Turner, S J ^a   Theaker, J M ^a   Howell, W M ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

HLA typing; Malignant melanoma; Polymerase chain reaction

Indexed keywords

HLA DQ ANTIGEN; HLA DQB1 ANTIGEN;

ARTICLE; CAUCASIAN; DISEASE COURSE; DISEASE PREDISPOSITION; GENETIC LINKAGE; HLA TYPING; HUMAN; MELANOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; FEMALE; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; MALE; SKIN TUMOR; UNITED KINGDOM;

EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GREAT BRITAIN; HLA-DQ ANTIGENS; HUMANS; MALE; MELANOMA; PROGNOSIS; SKIN NEOPLASMS;

EID: 0031594841     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1998.tb03025.x     Document Type: Article

References (32)

1. Cress RD, Holly EA. Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians and blacks: an analysis of California cancer registry data, 1988-93. Cancer Causes Control 1997: 8: 246-52.
2. Mackie RM, Hole DJ. Incidence and thickness of primary tumours and survival of patients with cutaneous malignant melanoma in relation to socioeconomic status. Br Med J 1996: 312: 1125-8.
3. Walker GJ, Nancarrow DJ, Walters MK, Palmer JM, Weber JL, Hayward NK. Linkage analysis in familial melanoma kindreds to markers on chromosome 6p. Int J Cancer 1994: 59: 771-5.
4. Elder DE, Guerry D IV, Epstein MN et al. Invasive malignant melanoma lacking competence for metastasis. Am J Dermatopathol 1984: 6 Suppl: 55-62.
5. Clark WH Jr, Elder DE, Guerry D IV et al. Model predicting survival in stage I melanoma based on tumour progression. J Natl Cancer Inst 1989: 81: 1893-904.
6. Wölfel T, Hauer M, Klehmann E et al. Analysis of antigens recognised on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL). Int J Cancer 1993: 55: 237-44.
7. Rivoltini L, Barracchini KC, Viggiano V et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 1995: 55: 3149-57.
8. Le Dréan E, Gervois N, Diez E, Semana G, Dreno B, Jotereau F. HLA class II-restricted recognition of common tumour epitopes on human melanoma cells by CD4+ melanoma-infiltrating lymphocytes. Eur J Immunol 1995: 25: 2732-6.
9. Bodmer JG, Tonks S, Oza AM et al. Hodgkin's disease study. In: Tsuji K, Aizawa M, Sasazaki T, ed. HLA 1991. Proceedings of the Eleventh International Histocompatibility Workshop and Conference, Vol 1. Oxford: Oxford University Press, 1992: 701-9.
10. Howell WM, Jones DB. The role of human leukocyte antigen genes in the development of malignant disease. J Clin Pathol Mol Pathol 1995: 48: M302-6.
11. Barger BO, Acton RT, Soong S-J, Roseman J, Balch C. Increase of HLA-DR4 in melanoma patients from Alabama. Cancer Res 1982: 42: 4276-9.
12. Mueller-Eckhardt G, Schendel DJ, Hundeiker M et al. Possible association between HLA-DR5 and superficial spreading malignant melanoma. Int J Cancer 1984: 34: 751-5.
13. Lee JE, Reveille JD, Ross MI, Platsoucas CD. HLA-DQB1*0301 association with increased cutaneous melanoma risk. Int J Cancer 1994: 59: 510-3.
14. Lee JE, Lu M, Mansfield PF, Platsoucas CD, Revielle JD, Ross MI. Malignant melanoma: relationship of the human leukocyte antigen class II gene DQB1*0301 to disease recurrence in American Joint Committee on Cancer stage I or II. Cancer 1996: 78: 758-63.
15. Marincola FM, Shamamain P, Rivoltini L et al. HLA associations in the antitumour response against malignant melanoma. J Immunother 1996: 18: 242-52.
16. Kageshita T, Naruse T, Hirai S et al. Molecular genetic analysis of HLA class II alleles in Japanese patients with melanoma. Tissue Antigens 1997: 49: 466-70.
17. Muto M, Ohmura A, Nakano J et al. HLA class I polymorphism and the susceptibility to malignant melanoma. Tissue Antigens 1996: 47: 447-9.
18. Pirozzi G, Mercuro O, Ionna F, Mozzillo N, Manzo C, Lombardi ML 1997. Analysis of HLA polymorphism in Italian melanoma patients. Ear J Immunogenet 1997: 24 Suppl 1: 42.
19. Bateman AC, Leung ST, Howell WM, Roche WR, Jones DB, Theaker JM. Detection of specimen contamination in routine histopathology by HLA class II typing using the polymerase chain reaction and sequence specific oligonucleotide probing. J Pathol 1994: 173: 243-8.
20. Howell WM, Leung ST, Jones DB et al. HLA-DRB, -DQA, and -DQB polymorphism in celiac disease and enteropathy-associated T-cell lymphoma. Hum Immunol 1995: 43: 29-37.
21. Kimura A, Sasazuki T. Eleventh International Histocompatibility Workshop reference protocol for the HLA DNA-typing technique. In: Tsuji K, Aizawa M, Sasazuki T, ed. HLA 1991, Vol. 1. Oxford: Oxford University Press, 1992: 397-439.
22. Beahrs OH, Myers MH. Manual for staging of cancer. American Joint Committee on Cancer. 2nd ed. Philadelphia: JB Lippincott, 1983: 117-22.
23. Dyer P, Warrens A. Design and interpretation of studies of the major histocompatibility complex in disease. In: Lechler R, ed. HLA and disease. London: Academic Press, 1994: 93-121.
24. Lee JE, Reveille JD, Platsoucas CD. Association of HLA DQB1*0301 with malignant melanoma. J Immunother 1996: 19: 381-3.
25. Terasaki PI, Gjertson DW. HLA 1997. Los Angeles (CA): UCLA Tissue Typing Laboratory, 1997.
26. Lulli P, Grammatico P, Brioli G et al. HLA-DR and -DQ alleles in Italian patients with melanoma. Tissue Antigens 1998: 51: 276-80.
27. Lee JE, Loflin PT, Laud PR, Lu M, Reveille JD, Lawlor DA. The human leukocyte antigen TAP2 gene defines the centromeric limit of melanoma susceptibility on chromosome 6p. Tissue Antigens 1996: 47: 117-21.
28. Van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognised by cytolytic T lymphocytes on a human melanoma. Science 1991: 254: 1643-7.
29. Lazaris AC, Theodoropolous GE, Aroni K, Saetta A, Davaris PS. Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA DR molecules in malignant melanoma. Virchows Arch 1995: 426: 461-7.
30. Brady MS, Eckels DD, Ree SV, Schultheiss KE, Lee JS. MHC class II-mediated antigen presentation by melanoma cells. J Immunother 1996: 19: 387-97.
31. Van Duinen SG, Ruiter DJ, Broecker EB et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 1988: 48: 1019-25.
32. Becker JC, Brocker EB. Lymphocyte-melanoma interaction: role of surface molecules. Recent Results Cancer Res 1995: 139: 205-14.